Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency

J Pediatr. 2003 Sep;143(3):402-5. doi: 10.1067/S0022-3476(03)00294-4.

Abstract

Prednisolone has unknown growth-suppressing effects relative to other steroids. We retrospectively studied 9 children (6 with congenital adrenal hyperplasia, CAH) receiving hydrocortisone replacement after switching to prednisolone (dose ratio, 1:5). Growth velocity and, in patients with CAH, 17-OHP decreased significantly. Dose reduction reversed these effects. Roughly, growth suppression relative potency for prednisolone:hydrocortisone was 15:1.

MeSH terms

  • Adrenal Hyperplasia, Congenital / drug therapy*
  • Adrenal Insufficiency / drug therapy*
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / pharmacokinetics*
  • Anti-Inflammatory Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Female
  • Growth Disorders / chemically induced*
  • Humans
  • Hydrocortisone / adverse effects
  • Hydrocortisone / pharmacokinetics*
  • Hydrocortisone / therapeutic use*
  • Infant
  • Male
  • Prednisolone / adverse effects
  • Prednisolone / pharmacokinetics*
  • Prednisolone / therapeutic use*
  • Retrospective Studies
  • Therapeutic Equivalency

Substances

  • Anti-Inflammatory Agents
  • Prednisolone
  • Hydrocortisone